With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …

Cancer patients treated with immune checkpoint inhibitors (ICIs) are susceptible to a broad
and variable array of immune‐related adverse events (irAEs). With increasing clinical use of …

Introduction We aimed to comprehensively investigate the causal relationship between 731
immune cell traits and autoimmune thyroiditis (AIT) and to identify and quantify the role of …

Cytokines are proteins used by immune cells to communicate with each other and with cells
in their environment. The pleiotropic effects of cytokine networks are determined by which …

The emergence of immune checkpoint inhibitors (ICIs) has heralded a transformative era in
the therapeutic landscape of non‐small cell lung cancer (NSCLC). While ICIs have …

Biomarkers are critical to the staging and diagnosis of type 1 diabetes (T1D). Functional
biomarkers offer insights into T1D immunopathogenesis and are often revealed using …

Abstract Programmed-cell-death 1 (PD-1) expression is associated not only with T-cell
activation but with exhaustion. Specifically, PD-1+ T cells present an exhausted phenotype …

Immune checkpoint inhibitors (ICIs) frequently cause immune-related adverse events
(irAEs), with thyroid irAEs being the most common endocrine-related irAEs. The incidence of …

Hashimoto's thyroiditis (HT) is a chronic autoimmune disorder primarily driven by T cell. The
apoptosis of the follicular thyroid cells plays an important role in HT apart from the …

Autoimmune thyroiditis (AITD) is a prevalent autoimmune disorder characterized by the
immune system's attack on thyroid tissue, potentially leading to thyroid dysfunction, with a …